BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.
New KEYNOTE-B96 data add to previous results showing progression-free survival (PFS) and overall survival (OS) improvements ...
Kelly Rachal was 26 when she learned she had ovarian cancer. After a routine ultrasound found her ovaries covered in masses, ...
Without an easy way to screen and with nondescript symptoms, ovarian cancer is often caught in late stages, requiring massive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback